SCHEMBL2762879

SCHEMBL2762879

COc1ccc2c(c1)CCc1sc(NS(=O)(=O)c3ccc(Cl)c(Cl)c3Cl)nc1-2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.58
TP53 P04637 7/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
ALDH1A1 P00352 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
HPGD P15428 4/20 0.54
KDM4E B2RXH2 3/20 0.54
CYP1A2 P05177 3/20 0.54
CYP3A4 P08684 3/20 0.54
CYP2C9 P11712 3/20 0.54
CYP2C19 P33261 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
DYRK1A Q13627 1/20 0.52
ADORA1 P30542 1/20 0.51
RAB9A P51151 3/20 0.51
LMNA P02545 3/20 0.50
RXFP1 Q9HBX9 1/20 0.48
TDP2 O95551 2/20 0.47
APAF1 O14727 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762860 0.93 MAPT (0.56) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762669 0.85 MAPT (0.56) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762411 0.84 MAPT (0.62) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762933 0.83 MAPT (0.59) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762753 0.81 MAPT (0.58) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2763423 0.80 MAPT (0.59) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762865 0.78 MAPT (0.57) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762862 0.76 MAPT (0.56) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762858 0.76 MAPT (0.56) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL2762497 0.71 MAPT (0.46) MAPTTP53SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP claimed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MAPT 3275/4885TP53 4272/4885SMN1; SMN2 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.